Skip to main content
SpringerLink
Log in

Prognostic and Predictive Biomarkers for Men With Castration-Resistant Prostate Cancer

  • Living reference work entry
  • First Online:
Biomarkers in Cancer

Abstract

Despite significant advances in diagnosis and management, prostate cancer is still a leading cause of cancer-related death in men. Castration-resistant prostate cancer (CRPC) is defined by disease progression despite androgen deprivation and castrate levels of testosterone. There have been a rapidly increasing number of new systematic agents which have been approved by the USFDA for men with metastatic CRPC, based on the results of successful phase 3 trials of a diverse range of agents with immunomodulatory, hormonal, bone-targeting, and microtubule-targeting mechanisms of action. Therefore, it is becoming essential to understand the optimal and rational combination and sequences of these treatments in the clinic, as well as to identify patients most likely to benefit from a specific treatment. Minimizing harms and costs of ineffective therapies is an equally important goal. Predictive biomarkers linked to relevant clinical outcomes are thus needed in drug development in CRPC, and there is an increasing need for these biomarkers to guide a clinician’s decision. We discuss in this chapter existing and emerging prognostic and predictive biomarkers in CRPC and future directions of biomarker development in men with CRPC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–904.

    Article  PubMed  Google Scholar 

  • Antonarakis ES, Lu C, Wang H, Luber B, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028-38.

    Google Scholar 

  • Aparicio A, Den R, et al. Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol. 2011;8(10):562–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Aparicio A, Harzstark A, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19:3621–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Armstrong AJ, Garrett-Mayer ES, et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007a;13:6396–403.

    Article  CAS  PubMed  Google Scholar 

  • Armstrong AJ, Garrett-Mayer E, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone- refractory prostate cancer. J Clin Oncol. 2007b;25:3965–70.

    Article  PubMed  Google Scholar 

  • Armstrong AJ, Tannock IF, et al. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010a;46:517–25.

    Article  CAS  PubMed  Google Scholar 

  • Armstrong AJ, Garrett-Mayer E, et al. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010b;16:203–11.

    Article  CAS  PubMed  Google Scholar 

  • Armstrong AJ, Marengo MS, Oltean S, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011;9:997–1007.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol. 2012;30:3402–7.

    Article  CAS  PubMed  Google Scholar 

  • Armstrong AJ, et al. Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod. J Clin Oncol. 2013;31:(suppl; abstr 5081).

    Google Scholar 

  • Attard G, Swennenhuis JF, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009;69:2912–8.

    Article  CAS  PubMed  Google Scholar 

  • Beltran H, Rickman DS, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Berruti A, Vignani F, et al. Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle. Open Access J Urol. 2010;2:109–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Berthold DR, Pond GR, et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008a;14:2763–7.

    Article  CAS  PubMed  Google Scholar 

  • Berthold DR, Pond GR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008b;26:242–5.

    Article  CAS  PubMed  Google Scholar 

  • Bitting RL, Healy P, et al. Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2013;31 Suppl. Abstract 5031.

    Google Scholar 

  • Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59–69.

    Article  CAS  PubMed  Google Scholar 

  • Bubendorf L, Schopfer A, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol. 2000;31:578–83.

    Article  CAS  PubMed  Google Scholar 

  • Budd G, Cristofanilli M, Ellis M, et al. Circulating tumor cells versus imaging – predicting overall survival invmetastatic breast cancer. Clin Cancer Res. 2006;12:6403–9.

    Article  CAS  PubMed  Google Scholar 

  • Chao NU, Choi M, et al. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer. 2006;119(8):1858–62.

    Article  Google Scholar 

  • Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–9.

    Article  PubMed  Google Scholar 

  • Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925–35.

    Article  CAS  PubMed  Google Scholar 

  • Comstock CES, Augello MA, et al. Targeting cell cycle and hormone receptor pathways in cancer. Oncogene. 2013;32(48):5481–5491.

    Google Scholar 

  • Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.

    Article  CAS  PubMed  Google Scholar 

  • Dahut WL, Scripture C, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res. 2008;14(1):209–14.

    Article  CAS  PubMed  Google Scholar 

  • Danila DC, Anand A, Sung CC, et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol. 2011;60:897–904.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • de Bono JS, Scher HI, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–9.

    Article  PubMed  Google Scholar 

  • de la Piedra C, Alcaraz A, et al. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. Br J Cancer. 2013;108:2565–72.

    Article  PubMed Central  PubMed  Google Scholar 

  • Dennis ER, Jia X, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012;30:519–24.

    Article  PubMed Central  PubMed  Google Scholar 

  • Domingo-Domenech J, Vidal S, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012;22:373–88.

    Article  CAS  PubMed  Google Scholar 

  • Ebrahimi B, Tucker SL, et al. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 2004;101:2727–36.

    Article  CAS  PubMed  Google Scholar 

  • El Sheikh SS, Romanska HM, et al. Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer – a pilot study. Neoplasia. 2008;10:949–53.

    Article  PubMed Central  PubMed  Google Scholar 

  • Even-Sapir E, Metser U, et al. The detection of bone metastases in patients with high risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single and multifield of view SPECT, 18 F- fluoride PET and 18 F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.

    PubMed  Google Scholar 

  • FDA. CellSearch(TM) Circulating Tumor Cell Kit. Premarket notification – expanded indications for use – metastatic prostate cancer. http://www.accessdata.fda.gov/cdrh_docs/pdf7/K073338.pdf (2008).

  • Halabi S, Small EJ, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232–7.

    Article  PubMed  Google Scholar 

  • Halabi S, Ou S, Vogelzang NJ, et al. The prognostic value of change in hemoglobin (HGB), LDH and PSA levels at 3 months from baseline in men with castrate recurrent prostate cancer [abstract]. American Society of Clinical Oncology Prostate Cancer Symposium; 2007 Feb 22–24; Orlando.

    Google Scholar 

  • Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008;26:2544–9.

    Article  PubMed  Google Scholar 

  • Holzbeierlein J, Lal P, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217–27.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Hörnberg E, Ylitalo EB, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One. 2011;6:e19059.

    Article  PubMed Central  PubMed  Google Scholar 

  • Huang J, Yao JL, di Sant’Agnese PA. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate. 2006;66:1399–406.

    Article  CAS  PubMed  Google Scholar 

  • Humphreys MR, Fernandes KA, Sridhar SS. Impact of age at diagnosis on outcomes in men with castrate-resistant prostate cancer (CRPC). J Cancer. 2013;4(4):304–14.

    Article  PubMed Central  PubMed  Google Scholar 

  • Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;3:276–85.

    Article  CAS  PubMed  Google Scholar 

  • Hussain M, Tangen CM, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984–90.

    Article  PubMed  Google Scholar 

  • Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. ASCO 2011 annual meeting. J Clin Oncol. 2011;29S. Abstract 4516.

    Google Scholar 

  • Imbriaco M, Larson SM, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan index. Clin Cancer Res. 1998;4:1765–72.

    CAS  PubMed  Google Scholar 

  • Jung K, Miller K, et al. Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. Eur Urol. 2011;59:604–12.

    Article  CAS  PubMed  Google Scholar 

  • Kantoff PW, Higano CS, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.

    Article  CAS  PubMed  Google Scholar 

  • Karantanos T, et al. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Keizman D, Gottfried M, et al. Castration-resistant prostate cancer patients treated with ketoconazole: pretreatment neutrophil-to-lymphocyte ratio in metastatic association with outcome and predictive nomogram. Oncologist. 2012;17:1508–14.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Kelly WK, Halabi S, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Komiya A, Yasuda K, et al. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients. Mol Clin Oncol. 2013;1:257–62.

    PubMed Central  PubMed  Google Scholar 

  • Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13(12):1210–7.

    Article  CAS  PubMed  Google Scholar 

  • Mahon KL, Chatfield MD, et al. Cytokines’ profiles to predict chemotherapy outcome in castration-resistant prostate cancer (CRPC). ASCO annual meeting proceedings (Post-Meeting Edition). J Clin Oncol. 2011;29 Suppl:4598.

    Google Scholar 

  • Marín-Aguilera M, Codony-Servat J, et al. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther. 2012;11:329–39.

    Article  PubMed  Google Scholar 

  • McNeel DG, Lin DW, Gardner T, et al. Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients with metastatic castrate-resistant prostate cancer. J Clin Oncol. 2012;30(suppl; abstract 4650).

    Google Scholar 

  • Morgan T, Lange P, et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res. 2009;15:677–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Morris MJ, Akhurst T, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005;11:3210–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Mulholland D, Tran L, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011;19:792–804.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Nanus DM, Loftus M, Akhtar NH, et al. Prospective analysis of prostate cancer (PC) circulating tumor cells (CTCs) to predict response to docetaxel (DOC) chemotherapy. J Clin Oncol. 2012;30(Suppl 5; abstract 100).

    Google Scholar 

  • Olmos D, Brewer D, Clark J, et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol. 2012;11:1114–24.

    Article  Google Scholar 

  • Ozkumur E, Shah A, et al. Inertial focusing for tumor antigen–dependent and –independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5(179):179ra47.

    Google Scholar 

  • Parker C, Heinrich D, et al. Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer. 2011;47 Suppl 2. Abstract 1LBA.

    Google Scholar 

  • Parker C, Nilsson S, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

    Article  CAS  PubMed  Google Scholar 

  • Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate- specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006;98:516–21.

    Article  PubMed  Google Scholar 

  • Ploussard G, Terry S, Maille P, et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res. 2010;70:9253–64.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Pond GR, Armstrong AJ, Wood BA, et al. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int. 2012;110(11 Pt B):E461–8.

    Article  CAS  PubMed  Google Scholar 

  • Pound CR, Partin AW, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–7.

    Article  CAS  PubMed  Google Scholar 

  • Prins RC, Rademacher BL, et al. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol. 2012;30:33–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Ross RW, Galsky MD, Scher HI, et al. A whole-blood RNA transcript based transcript based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012;11:1105–13.

    Article  Google Scholar 

  • Ryan CJ, Li J, Kheoh T, et al. Baseline serum adrenal androgens are prognostic and predictive of overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): results of the COU-AA-301 phase 3 randomized trial. Cancer Res. 2012;72:S1. Abstract LB-434.

    Google Scholar 

  • Sasaki T, Komiya A, Suzuki H, et al. Changes in chromogranin A serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol. 2005;48:224–30.

    Article  CAS  PubMed  Google Scholar 

  • Saylor PJ, Armstrong AJ, et al. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 2013;63:309–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Schellhammer PF, Chodak G, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology. 2013;81:1297–302.

    Article  PubMed  Google Scholar 

  • Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59.

    Article  PubMed Central  PubMed  Google Scholar 

  • Scher H, Jia X, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10:233–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011a;29:3695–704.

    Article  PubMed Central  PubMed  Google Scholar 

  • Scher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel (Meeting Abstracts). J Clin Oncol. 2011b;29:LBA4517.

    Google Scholar 

  • Seruga B, Zhang H, et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8:887–99.

    Article  CAS  PubMed  Google Scholar 

  • Shaffer DR, Leversha MA, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:2023–9.

    Article  CAS  PubMed  Google Scholar 

  • Shafique K, Proctor M, et al. The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer. 2013;13:292–300.

    Article  PubMed Central  PubMed  Google Scholar 

  • Sharma A, Comstock CES, et al. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res. 2007;67:6192–203.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Sharma A, Yeow WS, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest. 2010;120:4478–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Sissung T, Danes R, et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther. 2008;7:19–26.

    Article  CAS  PubMed  Google Scholar 

  • Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972–82.

    Article  PubMed  Google Scholar 

  • Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918–25.

    Article  PubMed  Google Scholar 

  • Sonpavde G, Pond GR, Berry WR, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2010;5:607–13.

    Google Scholar 

  • Spiess PE, Pettaway CA, Vakar-Lopez F, et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer. 2007;110:1729–37.

    Article  PubMed  Google Scholar 

  • Subudhi SK, Heller G, et al. Sera cytokine levels to predict survival in men with progressive castration-resistant prostate cancer. J Clin Oncol. 2013;13 Suppl. Abstract 5083.

    Google Scholar 

  • Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Thadani-Mulero M, Portella L, Sun S, Sung M, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014;74(8):2270–82.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004;350:2239–46.

    Article  CAS  PubMed  Google Scholar 

  • Tol J, Koopman M, et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2010;21:1006–12.

    Article  CAS  PubMed  Google Scholar 

  • Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8.

    Article  CAS  PubMed  Google Scholar 

  • Ulmert D, Kaboteh R, Fox JJ, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urol. 2012;62:78–84.

    Article  PubMed Central  PubMed  Google Scholar 

  • Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol. 2005;47:147–55.

    Article  CAS  PubMed  Google Scholar 

  • Vollmer RT, Dawson NA, Vogelzang NJ. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. Cancer. 1998;83:1989–94.

    Article  CAS  PubMed  Google Scholar 

  • Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer. 2014;21(4):T87–103.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Watahiki A, Macfarlane R, et al. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int J Mol Sci. 2013;14:7757–70.

    Article  PubMed Central  PubMed  Google Scholar 

  • Weckermann D, Polzer B, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009;27:1549–56.

    Article  PubMed  Google Scholar 

  • Yoshimoto M, Cutz JC, et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68 % of primary prostate cancer and 23 % of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet. 2006;169:128–37.

    Article  CAS  PubMed  Google Scholar 

  • Zhao L, Lee BY, et al. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res. 2009;69:7696–703.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke University and Cancer Institute, Durham, NC, USA

    Jing Li

  2. Duke Cancer Institute, Duke Prostate Center, Divisions of Medical Oncology and Urology, Duke University School of Medicine, 27710, Durham, NC, USA

    Andrew J. Armstrong

Authors
  1. Jing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew J. Armstrong
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nutrition and Dietetics Division of Diabetes &amp; Nutritional Sciences, Faculty of Life Sciences &amp; Medicine King’s College London, London, United Kingdom

    Victor R. Preedy

  2. Department of Biomedical Sciences Faculty of Science and Technology, University of Westminster, London, United Kingdom

    Vinood B. Patel

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this entry

Cite this entry

Li, J., Armstrong, A.J. (2014). Prognostic and Predictive Biomarkers for Men With Castration-Resistant Prostate Cancer. In: Preedy, V., Patel, V. (eds) Biomarkers in Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7744-6_13-1

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-7744-6_13-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Online ISBN: 978-94-007-7744-6

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation